In this video, learn why semaglutide and other GLP-1 agonists are so groundbreaking and how they may help a lot of people, according to Stacia Woodcock, PharmD, Pharmacy Editor at GoodRx.
Stacia Woodcock, PharmD, is a pharmacy editor for GoodRx. She earned her Doctor of Pharmacy degree from the University of Kentucky and is licensed in New York and Massachusetts.
References
American Society of Health-System Pharmacists. (2023). Semaglutide injection.
Collins, L., et al. (2022). Glucagon-like peptide-1 receptor agonists. StatPearls.
Novo Nordisk. (2022). Ozempic [package insert].
Novo Nordisk. (2022). Wegovy [package insert].
U.S. Food and Drug Administration. (2023). Drug compounding and drug shortages.
U.S. Food and Drug Administration. (2023). Medications containing semaglutide marketed for Type 2 diabetes or weight loss.
Why trust our experts?
